Genor Biopharma Holdings Limited (6998) AI Stock Analysis

• Market Cap: HK$1.36B
• Dividend Yield: N/A
• Average Volume (3M): 1.37M
• Price to Earnings (P/E): ―
• Beta (1Y): 0.46
• Revenue Growth: N/A
• EPS Growth: 92.45%
• Country: HK
• Employees: 24
• Sector: Healthcare
• Sector Strength: 46
• Industry: Biotechnology
• EPS (TTM): -0.11
• Shares Outstanding: 525,262,100
• 10 Day Avg. Volume: 1,449,538
• 30 Day Avg. Volume: 1,372,096
• PEG Ratio: 0.09
• Price to Book (P/B): 0.66
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -2.01
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0

• Rating: 51 Neutral
• Price Target: ―

Genor Biopharma's overall stock score reflects its current developmental stage as a biotech company with strong equity and cash reserves but significant operational challenges. Technical indicators show some positive momentum, but valuation remains a concern due to negative earnings. The absence of earnings call and corporate events data leaves the focus on financial and technical aspects.

Genor Biopharma Holdings Limited Business Overview & Revenue Model

Company Description

Genor Biopharma Holdings Limited (6998) is a biopharmaceutical company that specializes in the research, development, and commercialization of innovative therapeutics for the treatment of cancer and other life-threatening diseases. The company operates primarily in the biotechnology and pharmaceutical sectors, focusing on monoclonal antibodies and other biologic drugs. Genor Biopharma aims to address significant unmet clinical needs by advancing a diverse pipeline of products through strategic research and development efforts.

How the Company Makes Money

Genor Biopharma Holdings Limited generates revenue primarily through the commercialization of its proprietary biologic drugs and therapeutic products. The company’s revenue model includes sales of its approved drugs, licensing agreements, and strategic collaborations or partnerships with other pharmaceutical companies. These partnerships often involve co-development and co-commercialization arrangements, which can provide upfront payments, milestone payments, and royalties. Additionally, Genor Biopharma may engage in research and development service contracts, contributing further to its revenue streams. The company leverages its scientific expertise and innovative technology platforms to enhance product development and optimize its market presence.

Genor Biopharma Holdings Limited Financial Statement Overview

Summary

Genor Biopharma showcases a mixed financial profile typical of a biotech firm in developmental stages. While the company possesses strong equity and cash reserves, persistent net losses and negative cash flows highlight ongoing operational challenges. The low debt levels provide some stability, but the ability to transition into profitability remains uncertain.

Income Statement

Genor Biopharma has seen minimal revenue growth with sporadic revenue generation over the years. The company has consistently reported negative EBIT and net income, reflecting ongoing operational and profitability challenges. The gross profit margin is high, indicating the ability to cover direct costs, but the net profit margin remains negative, highlighting significant operating losses.

Balance Sheet

The company maintains a strong equity position compared to its liabilities, reflecting a healthy equity ratio. The debt-to-equity ratio is low, suggesting limited reliance on debt financing. However, the return on equity is negative, indicating that shareholders are not gaining returns on their investments due to persistent net losses.

Cash Flow

Genor Biopharma's cash flow statements show a history of negative free cash flow, suggesting challenges in generating cash from operations. The operating cash flow to net income ratio is weak, pointing to inefficiencies in converting income into cash flow. Despite this, the company maintains substantial cash reserves, which could provide a buffer for future operations.

Breakdown	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	206.23M	0.00	15.93M	0.00	10.33M
Gross Profit	204.89M	0.00	14.95M	0.00	7.74M
EBITDA	-5.15M	-551.01M	-675.89M	-819.50M	-2.98B
Net Income	-51.28M	-674.36M	-730.40M	-865.37M	-3.03B
Balance Sheet
Total Assets	1.29B	1.45B	2.12B	2.86B	3.57B
Cash, Cash Equivalents and Short-Term Investments	1.06B	1.17B	1.59B	2.20B	2.93B
Total Debt	911.00K	7.16M	28.59M	57.41M	31.06M
Total Liabilities	138.05M	256.18M	309.87M	369.73M	336.32M
Stockholders Equity	1.15B	1.19B	1.80B	2.49B	3.23B
Cash Flow
Free Cash Flow	-123.55M	-426.15M	-590.56M	-695.13M	-885.01M
Operating Cash Flow	-121.98M	-425.12M	-577.61M	-623.74M	-786.72M
Investing Cash Flow	8.01M	5.99M	-12.94M	-54.26M	-98.24M
Financing Cash Flow	-1.56M	-6.82M	-57.39M	17.57M	3.74B

Genor Biopharma Holdings Limited Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 2.53
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:6998, the sentiment is Positive. The current price of 2.53 is below the 20-day moving average (MA) of 2.66, above the 50-day MA of 2.42, and above the 200-day MA of 1.94, indicating a neutral trend. The MACD of 0.04 indicates Positive momentum. The RSI at 50.68 is Neutral, neither overbought nor oversold. The STOCH value of 16.46 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for HK:6998.

Genor Biopharma Holdings Limited Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
9997	82 Outperform	€8.86B	13.99	18.36%	25.22%	7.13%	13.39%
2318	79 Outperform	$997.37B	6.81		7.42%	11.71%	37.04%
2269	74 Outperform	$99.68B	28.65	8.17%	―	7.52%	-1.92%
Sector *	60 Neutral	HK$15.20B	5.43	-7.43%	6.05%	11.72%	-20.69%
1873	58 Neutral	HK$3.28B	18.25	4.47%	―	-9.75%	―
6998	51 Neutral	HK$1.36B	―	-4.30%	―	―	92.45%
6185	48 Neutral	HK$10.78B	―	-4.41%	―	94.98%	85.69%

Genor Biopharma Holdings Limited Corporate Events

Genor Biopharma Extends CEO’s Term to Strengthen Leadership

Genor Biopharma Holdings Limited has announced the extension of Dr. Guo Feng’s term as CEO for an additional two years, effective from April 16, 2025, to April 15, 2027. This decision reflects the company’s confidence in Dr. Guo’s leadership and his extensive experience in the biopharmaceutical industry, which is expected to benefit the company’s strategic direction and operational management.

Genor Biopharma Announces Strategic Merger and Listing Plans

Genor Biopharma Holdings Limited has announced a series of strategic transactions, including a proposed merger, a new listing application, and an increase in authorized share capital. These initiatives are aimed at expanding the company’s market presence and operational capabilities. However, the completion of these transactions is contingent upon regulatory approvals and shareholder agreements, which introduces uncertainty regarding their finalization.

Genor Biopharma Reports 2024 Financial Results and Strategic Merger with Edding

Genor Biopharma Holdings Limited announced its annual results for 2024, reporting a significant increase in revenue to approximately RMB206.2 million, primarily due to license and stock purchase agreements. The company also reported a decrease in research and development expenses and a total comprehensive loss of approximately RMB51.5 million, down from RMB676.0 million in 2023. Genor has optimized its structure to adopt an asset-light model, reducing costs and increasing efficiency. It has entered into a merger agreement with Edding, which will result in Edding’s shareholders holding 77% of the enlarged company. This strategic move aims to strengthen Genor’s commercial capabilities and maintain its competitive position in the pharmaceutical industry.

Genor Biopharma Announces Board Meeting for Annual Results

Genor Biopharma Holdings Limited, a company incorporated in the Cayman Islands, has announced that its board of directors will meet on March 28, 2025. The meeting will focus on considering and approving the company’s annual results for the year ended December 31, 2024, which will subsequently be published.

Genor Biopharma Announces Major Acquisition and Corporate Changes

Genor Biopharma Holdings Limited announced a very substantial acquisition involving a proposed merger with a target company, which includes issuing consideration shares under a specific mandate. The announcement also covers a reverse takeover, a new listing application, a whitewash waiver application, and other corporate changes such as a proposed company name change and an increase in authorized share capital. The company has extended deadlines for the new listing application and merger closing, and is preparing the necessary documentation for shareholders. The merger’s completion is contingent on several conditions, including approvals from the Stock Exchange and shareholders, with updates to be provided as developments occur.

Genor Biopharma Announces Auditor Change Following EGM

Genor Biopharma Holdings Limited, a company incorporated in the Cayman Islands, held an Extraordinary General Meeting (EGM) on February 19, 2025, where all proposed resolutions were unanimously passed. The key decision from the EGM was the removal of PwC as the Company’s auditor and the immediate appointment of EY to the position. This change in auditors may signal a strategic shift or a response to specific business needs, impacting the company’s operational strategies and possibly influencing stakeholder perception.